Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 3,754,300 | 3,675,600 | 3,028,700 | 3,789,200 | 3,720,700 |
| Cost of Goods | 521,600 | 530,200 | 464,300 | 565,400 | 491,100 |
| Gross Profit | 3,232,700 | 3,145,400 | 2,564,400 | 3,223,800 | 3,229,600 |
| Operating Expenses | 2,206,500 | 2,066,100 | 1,973,000 | 2,234,001 | 2,050,200 |
| Operating Income | 1,026,800 | 1,079,500 | 591,700 | 990,200 | 1,179,500 |
| Interest Expense | 19,300 | 3,600 | 8,700 | 10,500 | 13,800 |
| Other Income | 755,800 | 442,800 | 322,000 | -21,600 | 327,300 |
| Pre-tax Income | 1,763,300 | 1,518,700 | 905,000 | 958,100 | 1,493,000 |
| Income Tax | 303,300 | 127,100 | 96,300 | 40,400 | 152,400 |
| Net Income Continuous | 1,460,000 | 1,391,600 | 808,700 | 917,700 | 1,340,600 |
| Net Income | $1,460,000 | $1,391,600 | $808,700 | $917,700 | $1,340,600 |
| EPS Basic Total Ops | 14.09 | 13.24 | 7.58 | 8.55 | 12.40 |
| EPS Basic Continuous Ops | 14.09 | 13.24 | 7.58 | 8.55 | 12.40 |
| EPS Diluted Total Ops | 13.62 | 12.81 | 7.27 | 8.12 | 11.54 |
| EPS Diluted Continuous Ops | 13.62 | 12.81 | 7.27 | 8.12 | 11.54 |
| EPS Diluted Before Non-Recurring Items | 9.63 | 10.72 | 6.43 | 9.90 | 11.73 |
| EBITDA(a) | $1,163,500 | $1,214,600 | $718,600 | $1,116,599 | $1,301,200 |